TherapeuticsMD, Inc. is a pharmaceutical royalty company that earns income from licensing its women’s healthcare products to third party commercializers. The firm does not manufacture or sell drugs directly. Instead it holds trademarks patents and other intellectual property related to products such as IMVEXXY BIJUVA ANNOVERA and prescription prenatal vitamins. Its business model relies on receiving royalty payments and milestone payments from partners who have the commercialization capabilities in the relevant territories. The company operates in the pharmaceutical industry with a focus on hormone therapy and contraceptive solutions. Prior to December 2022 TherapeuticsMD was engaged in the full cycle of drug development manufacturing and commercialization. After the Mayne Transaction it shifted to a pure royalty model and now functions as an intellectual property holding company. This shift allowed the firm to reduce operating expenses and concentrate on monetizing its existing asset base.

Revenue is generated primarily through royalty payments on net sales of licensed products in the United States and abroad. Under the Mayne License Agreement TherapeuticsMD receives a tiered royalty of 8.0 percent on the first 80 million dollars of annual net sales and 7.5 percent on sales above that threshold for a period of 20 years. In addition the company is eligible to receive milestone payments of five million ten million and fifteen million dollars when cumulative net sales of all products reach one hundred million two hundred million and three hundred million dollars respectively. The royalty rate will decrease to 2.0 percent on a product by product basis upon the earlier of patent expiration or generic launch in the United States. TherapeuticsMD also earns royalties from international licensees such as Knight Therapeutics in Canada and Israel and Theramex in Europe and other regions. The company may also receive prepaid royalties and other contingent consideration as part of its licensing arrangements. All manufacturing and development responsibilities have been transferred to the licensees so TherapeuticsMD’s income stream is passive and based on the commercial performance of its partners. The company’s financial statements reflect royalty revenue as license income and classify the former commercial operations as discontinued operations.

TherapeuticsMD occupies a niche as a pure play royalty holder in the women’s health segment of the pharmaceutical market. Its competitive advantage stems from a deep portfolio of patents and trademarks that protect its core products including IMVEXXY BIJUVA ANNOVERA and prenatal vitamin formulations. The company has outlicensed its assets to established commercial operators such as Mayne Pharma which reduces its operational risk and capital expenditure. While other firms in the royalty space may diversify across therapeutic areas TherapeuticsMD remains concentrated on hormone therapy and contraceptive products which allows it to develop specialized expertise in licensing negotiations. The firm’s long term royalty structures and milestone provisions provide predictable cash flows that differentiate it from traditional pharmaceutical companies that rely on product sales. Additionally the company’s intellectual property is actively defended through litigation and settlement agreements which helps to extend the effective market exclusivity of its products. Barriers to entry for potential competitors include the high cost of obtaining regulatory approval the complexity of patent landscapes and the necessity of establishing relationships with experienced commercial partners. TherapeuticsMD’s track record of securing long term agreements with reputable licensees further strengthens its position in the market.

The company’s customer base consists of pharmaceutical companies that hold licenses to commercialize its products. The primary licensee in the United States is Mayne Pharma LLC which holds exclusive rights to IMVEXXY BIJUVA ANNOVERA and the prenatal vitamin lines. Internationally TherapeuticsMD has granted exclusive licenses to Knight Therapeutics for Canada and Israel and to Theramex for the remainder of Europe and other selected markets. These partners are responsible for manufacturing distribution marketing and post approval compliance while TherapeuticsMD collects royalty income. The firm does not disclose a broad list of end users such as pharmacies or hospitals because its revenue is derived from business to business licensing arrangements. As of December 31 2025 the company reported a single full time employee serving in an executive role and relies on external consultants for financial IT legal and regulatory support. This lean structure reflects its transition to a royalty focused business model.